The inhibition of monoamine oxidase by 8-(2-phenoxyethoxy)caffeine analogues

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 11, 2012, Pages 513-518

  Strydom, B ^a   Bergh, J J ^a   Petzer, J P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

8 (2 phenoxyethoxy)caffeine; caffeine; monoamine oxidase; reversible inhibition; selective inhibition; structure activity relationship

Indexed keywords

8 (2 PHENOXYETHOXY)CAFFEINE DERIVATIVE; 8 [2 [4 (TRIFLUOROMETHYL)PHENOXY]ETHOXY]CAFFEINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CAFFEINE DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION;

CAFFEINE; MONOAMINE OXIDASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84869126262     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1323662     Document Type: Article

References (29)

1. Youdim MB H., Bakhle Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinsons disease and depressive illness. Br J Pharmacol: 2006; 147 S287 S296
2. Shih J. C., Chen K., Ridd M. J. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci: 1999; 22 197 217
3. Youdim MB H., Edmondson D. E., Tipton K. F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci: 2006; 7 295 309
4. Youdim MB H., Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology: 2004; 25 243 250
5. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev: 2003; 9 97 140
6. Fernandez H. H., Chen J. J. Monoamine oxidase-B inhibition in the treatment of Parkinsons disease. Pharmacotherapy: 2007; 27 174S 185S
7. Riederer P., Youdim MB H. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem: 1986; 46 1359 1365
8. Finberg J. P., Wang J., Bankiewich K. et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl: 1998; 52 279 285
9. Di Monte D. A., DeLanney L. E., Irwin I. et al. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res: 1996; 738 53 59
10. Rabey J. M., Sagi I., Huberman M. et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinsons disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol: 2000; 23 324 330
11. Tipton K. F., Boyce S., OSullivan J. et al. Monoamine oxidases: Certainties and uncertainties. Curr Med Chem: 2004; 11 1965 1982
12. Fowler J. S., Volkow N. D., Logan J. et al. Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal. Synaps: 1994; 18 86 93
13. Strydom B., Malan S. F., Castagnoli N. et al. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem: 2010; 18 1018 1028
14. Strydom B., Bergh J. J., Petzer J. P. 8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase. Eur J Med Chem: 2011; 46 3474 3485
15. Booysen H. P., Moraal C., TerreBlanche G. et al. Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase. Bioorg Med Chem: 2011; 19 7507 7518
16. 2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem: 2008; 16 8676 8684
17. 2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). Bioorg Med Chem: 2006; 14 3512 3521
18. 2A receptor antagonism. J Biol Chem: 2002; 277 36040 36044
19. Fischer E., Reese L. Ueber caffeïn, xanthin und guanin. Liebigs Ann Chem: 1883; 221 336 344
20. Sono M., Toyoda N., Shimizu K. et al. Functionalization including fluorination of nitrogen-containing compounds using electrochemical oxidation. Chem Pharm Bull: 1996; 44 1141 1145
21. Tsotinis A., Calogeropoulou T., Koufaki M. et al. Synthesis and antiretroviral evaluation of new alkoxy and aryloxy phosphate derivatives of 3'-azido-3'-deoxythymidine. J Med Chem: 1996; 39 3418 3422
22. Stenkamp D., Mueller S. G., Lustenberger P. et al. Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds. United States Patent Apr 13: 2005; PN 7 592 358
23. Huston R. C., Allen W. F. Caffeine derivatives. I. The 8-ethers of caffeine. J Am Chem Soc: 1934; 56 1356 1358
24. Baumann W. Die nervenkrankenfürsorge der stadt essen. Z Gesamte Neurol Psy: 1913; 15 114 121
25. Legoabe L. J., Petzer A., Petzer J. P. Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives. Eur J Med Chem: 2012; 49 343 353
26. Novaroli L., Reist M., Favre E. et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem: 2005; 13 6212 6217
27. Petzer A., Harvey B. H., Wegener G. et al., Azure B. a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharm: 2012; 58 403 409
28. Hubálek F., Binda C., Khalil A. et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem: 2005; 280 15761 15766
29. Son S-Y, Ma J., Kondou Y. et al. Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA: 2008; 105 5739 5744